SIRT1 belongs to the silent information regulator 2 (Sir2) protein family of enzymes and functions as a NAD + -dependent class III histone deacetylase. Here, we examined the anti-multiple myeloma (MM) activity of a novel oral agent, SRT1720, which targets SIRT1. Treatment of MM cells with SRT1720 inhibited growth and induced apoptosis in MM cells resistant to conventional and bortezomib therapies without significantly affecting the viability of normal cells. Mechanistic studies showed that anti-MM activity of SRT1720 is associated with: 1) activation of caspase-8, caspase-9, caspase-3, poly (ADP) ribose polymerase; 2) increase in reactive oxygen species; 2) induction of phosphorylated ataxia telangiectasia mutated/checkpoint kinase 2 signalling; 3) decrease in vascular endothelial growth factor-induced migration of MM cells and associated angiogenesis; and 4) inhibition of nuclear factor-κB. Blockade of ATM attenuated SRT1720-induced MM cell death. In animal tumour model studies, SRT1720 inhibited MM tumour growth. Finally, SRT1720 enhanced the cytotoxic activity of bortezomib or dexamethasone. Our preclinical studies provide the rationale for novel therapeutics targeting SIRT1 in MM.
Introduction
Recent studies have provided evidence for the potential clinical utility of targeting histone deacetylase (HDAC) enzymes in multiple myeloma (MM) (Catley et al, 2006; Hideshima et al, 2005) , and other haematological malignancies (Bhalla et al, 2009; Dai et al, 2008; Dasmahapatra et al 2010; Grant et al, 2007) . The sirtuins (SIRTs), also known as silent information regulator-2 (Sir2) proteins, consists of nicotinamide adenine dinucleotide Prior in vitro and in vivo studies using various cancer cell models show a role of SIRT1 either as an oncogene or a tumour suppressor gene. The oncogenic potential of SIRT1 is exemplified by studies showing that blockade of SIRT1, like other HDACs, triggers growth arrest and apoptosis in breast, colon and lung cancers (Ford et al, 2005; Heltweg et al, 2006; Ota et al, 2006) . In contrast, the tumour suppressor function of SIRT1 is evident from several in vivo and in vitro studies showing that SIRT1 is proapoptotic and anti-proliferative (Chua et al, 2005; Firestein et al, 2008; Fu et al, 2006; Wang et al, 2008; Yeung et al, 2004) . For example, mouse embryonic fibroblastsobtained from SIRT1-null mice are susceptible to spontaneous immortalization, implicating a growth-suppressive function of SIRT1 (Chua et al, 2005) . Haematopoietic stem cells from SIRT1-null mice exhibit enhanced proliferation ability, and shRNA knockdown of SIRT1 in human fibroblasts accelerates cell proliferation (Abdelmohsen et al, 2007; Narala et al, 2008) . Another study showed that SIRT1 blocks androgen receptor-dependent growth in prostrate cancer cells (Fu et al, 2006) . Biochemical inhibition of SIRT1 with specific inhibitors has not been shown to prevent proliferation of multiple cancer cell lines (Kamel et al, 2006; Solomon et al, 2006; Stunkel et al, 2007) . Ectopic expression of SIRT1 led to reduced proliferation in colon cancer cell lines and attenuated tumour growth in animal models (Kabra et al, 2009) ; and conversely, SIRT1-deficiency resulted in an increased tumour formation in p53-null mice (Wang et al, 2008) . Finally, SIRT1 was found to inhibit β-catenin, a member of Wnt signalling pathway, resulting in suppression of intestinal tumourigenesis and colon cancer growth (Firestein et al, 2008) . These studies support the potential of SIRT1 as tumour suppressor, and provide the rationale for preclinical evaluation of activators of SIRT1 in the treatment of cancer.
Materials and Methods

Cell culture
MM cell lines including MM.1S (dexamethasone-sensitive), MM.1R (dexamethasoneresistant), RPMI-8226, LR-5 (melphalan-resistant derivative of RPMI-8226), U266, KMS12, and INA-6 (interleukin-6 dependent) were cultured with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 units/ml Pencillin and 100 ug/ml streptomycin. Tumour cells from MM patients were purified (greater than 95% purity) by CD138 positive selection using the Auto MACS magnetic cell sorter (Miltenyi Biotec Inc., Auburn, CA). Informed consent was obtained from all patients in accordance with the Helsinki protocol. Peripheral blood mononuclear cells (PBMCs) from healthy donors were maintained in culture medium, as above. PBMCs were also labelled with CD19 microbeads for direct magnetic isolation of B-cells by positive selection using Auto MACS magnetic cell sorter (Miltenyi Biotec Inc.). The magnetically sorted CD19-positive cells were further stained with human CD20-fluoescein isothiocycante (FITC) antibody (Miltenyi Biotec Inc.) and analysed by flow cytometry. SRT1720 was obtained from Sirtris (Cambridge, MA); bortezomib was purchased from Selleck Chemicals LLC (Houston, TX); and dexamethasone was obtained from Calbiochem (San Deigo, CA).
Fluor de Lys Deacetylase Assay
Deacetylase activity of SIRT1 was measured using the Fluor de Lys Deacetylase kit (BIOMOL international Inc, Plymouth Meeting, PA) according to the manufacturer's instructions. Briefly, 4 × 10 4 cells were plated in 50 μl of medium containing 200 μM flourde lys substrate; the plate was then incubated for 5 h at 37°C, followed by addition of 100 μl of 2 μM Trichostatin A developing solution. After further incubation for 15 min at 37°C, the fluorescence was measured using SpectraMax M5 Multi-Mode Microplate Readers (Molecular Devices, Inc., Sunnyvale, CA).
Cell viability and apoptosis assays
Cell viability was assessed with a colorimetric assay using 3-(4, 5-dimethylthiozol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT; Calbiochem) as described previously (Hideshima et al, 2000) . Apoptosis assay was quantified using Annexin V-FITC/Propidium iodide (PI) apoptosis detection kit, as per manufacturer's instructions (BD Biosciences, San Jose, CA), followed by analysis on FACS Calibur (BD Biosciences).
Western blotting and protein quantification
Immunoblot analysis was performed using antibodies against caspase-3, caspase-7, caspase-8, caspase-9, poly (ADP) ribose polymerase (PARP) (Cell Signaling, Beverly, MA), Ace-Lys 382 p53, phosphorylated-ataxia telangiectasia mutated (pATM), phosphorylatedcheckpoint kinase 2 (pCHK2), phosphorylated-IκB ser32/36, and GAPDH (Abcam, Cambridge, MA). Blots were then developed by enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL). Densitometry of protein bands was acquired using an AlphaImager EC gel documentation system (Alpha Innotec, Kasendorf, Germany), and bands were analysed using the spot densitometry analysis tool (Alpha Ease FC software, version, 4.1.0).
Human plasmacytoma xenograft model
All animal studies were approved by the Institutional Animal Care and Use Committee of the Dana Farber Cancer Institute. The xenograft tumour model was performed as previously described (LeBlanc et al, 2002 ). This animal model has been immensely useful in extensively validating the novel anti-MM therapies, bortezomib and lenalidomide, leading to their translation to clinical trials and US Food and Drug Administration approval for the treatment of MM. Fox Chase-SCID mice (6 mice each group) were subcutaneously inoculated with 6.0 × 10 6 MM.1S cells in 100 μl of serum-free RPMI-1640 medium. When tumours were measurable (~100 mm 3 ) approximately three weeks after MM cell injection, mice were treated orally with vehicle alone (20% PEG400/0.5% Tween80/79.5% deionized water) or SRT1720 (200 mg/kg) for four weeks on a five consecutive days/week schedule.
In situ detection of apoptosis using immunohisto-chemistry (IHC)
Tumours from vehicle (control)-and SRT1720-treated mice were excised and preserved in 10% formalin. Apoptotic cells in tumours were identified by IHC staining for caspase-3 activation, as previously described (Chauhan et al, 2010) .
In vitro migration and capillary-like tube structure formation assays
Transwell Insert Assays (Chemicon, Billerica, MA) were utilized to measure migration as previously described (Podar et al, 2001) . In vitro angiogenesis was assessed by Matrigel capillary-like tube structure formation assay (Chauhan et al, 2010) . For endothelial tube formation assay, human vascular endothelial cells (HUVECs) were obtained from Clonetics (Walkersville, MD) and maintained in endothelial cell growth medium-2 (EGM2 MV SingleQuots, Clonetics) containing 5% FBS. After three passages, HUVEC cell viability was measured with the trypan blue exclusion assay, and <5% of cell death was observed with SRT1720 treatment.
Statistical Analysis
Statistical significance of differences observed in drug-treated vs. control cultures was determined by the Student's t test. The minimal level of significance was P < 0.05. Tumour volume in mice was measured using the GraphPad PRISM (GraphPad Software, SanDiego, CA).
Results
SRT-1720 targets SIRT1
We confirmed the functional specificity of SRT1720 against SIRT1 using different experimental strategies. For these studies, we first utilized the Fluor de Lys Deacetylase assay to measure whether SRT1720 affects SIRT1 deacetylase enzymatic activity. Treatment of MM.1R and RPMI-8226 MM cells with SRT1720 markedly increased the deacetylating activity; conversely, pre-treatment of cells with nicotinamide, an inhibitor of SIRT1, significantly blocked SRT1720-triggered deacetylating activity (Fig 1A) . Secondly, immunoblot analysis using antibodies specific against acetylated p53 (a known substrate of SIRT1) showed a marked decrease in acetylated state of p53 in SRT1720-treated MM cells ( Fig 1B) . Our data is in agreement with previous reports showing that SRT1720-induced biological effects occur via SIRT1 (Bhardwaj et al, 2007; Funk et al, 2010; Yoshizaki et al, 2009 ).
Anti-MM activity of SRT1720
Human MM cell lines (MM.1S, MM.1R, RPMI-8266, LR-5, INA6, KMS12, U266) were treated with various concentrations of SRT1720 for 24 h, followed by assessment for cell viability using MTT assays. A significant concentration-dependent decrease in viability of all cell lines was noted in response to treatment with SRT1720 ( Fig 1C; P < 0.005 for all cell lines; n=3). To determine whether SRT1720 similarly affects purified patient cells, tumour cells from six MM patients relapsing after multiple prior therapies including dexamethasone, melphalan, bortezomib, or lenalidomide and were treated for 24 h with SRT1720, followed by assessment for cell viability. A significant decrease in cell viability of all patient tumour cells was noted after SRT1720 treatment ( Fig 1D ; IC 50 range: 3-5 μM; P < 0.005 for all patients). Patients were considered refractory to specific therapy when disease progressed on therapy or relapsed within two months of stopping therapy. Similar to our data using drug resistant cell lines, we found responses in patient-derived tumour cells, including those resistant to therapies such as bortezomib, dexamethasone, or lenalidomide. A similar response to SRT1720 treatment was noted in two untreated patient MM cells (data not shown). Importantly, the 50% inhibitory concentration (IC 50 ) for MM cells of SRT1720 is at concentrations that do not significantly affect viability of normal lymphocytes ( Fig 1E; n =2). Higher concentrations of SRT1720 (15 μM) induced a modest (10-20%) decrease in normal cell viability. Additionally, treatment of B cells obtained from normal healthy donors with SRT1720 showed no marked decrease in the viability of these cells (Fig 1F) . Together, our data demonstrate that SRT1720 triggers cytotoxicity in MM cells, without significant toxicity in normal PBMCs.
We next examined whether the SRT1720-triggered decrease in viability was due to apoptosis. SRT1720 induced a significant increase in the Annexin V + /PI − apoptotic cell population in RPMI-8226 and MM.1R cells (Fig 1G; P < 0.04, n=3) . Moreover, treatment of both MM.1R and RPMI-8226 cells with SRT1720 triggered a marked increase in proteolytic cleavage of PARP (Lazebnik et al, 1994) , a signature event during apoptosis (Fig 1H and  1I ).
Mechanisms mediating anti-MM activity of SRT1720
Mitochondria mediate apoptotic signalling via activation of the cell death initiator caspase, pro-caspase 9 (intrinsic apoptotic pathway) (Bossy-Wetzel & Green 1999) . Similarly, Fas associated death-domain (FADD) protein is an essential part of the death-inducing signalling complexes (DISCs) that assemble upon engagement of tumour necrosis factor receptor family members, such as Fas, resulting in proteolytic processing and autoactivation of procaspase-8 (extrinsic apoptotic pathway) (Strasser et al, 2000) . Our data show that SRT1720 induced activation of both casapse-8 and caspase-9 apoptotic pathways (Fig 2A) . Both caspase-9 and caspase-8 are known to activate a common downstream effector procapsase-3 (Miller, 1999) , and our data further showed that SRT1720 triggered caspase-3 activation, as evidenced by caspase-3 cleavage (Fig 2A) . Moreover, SRT1720-induced apoptosis in MM cells was associated with generation of reactive oxygen species (ROS) (Fig 2B and 2C) , suggesting disruption of mitochondrial integrity (Miller, 1999) . Together, these findings suggest that SRT1720-induced apoptosis in MM cells occurs via both mitochondriaindependent and mitochondria-dependent apoptotic signalling pathways.
SIRT1 plays an important role in DNA damage response and DNA repair activity Wang et al, 2008) . The DNA damage response is, in part, mediated via activation of ATM, a serine/threonine protein kinase that is recruited and activated by DNA doublestrand breaks. ATM phosphorylates several key proteins that activate DNA damage checkpoint, thereby triggering cell cycle arrest, DNA repair or apoptosis (Yuan & Seto 2007) . Given that SIRT1 is linked to DNA damage response Wang et al, 2008) , and SRT1720 targets SIRT1 (Funk et al, 2010; Yoshizaki et al, 2009) , we next examined whether SRT1720 triggers the ATM-mediated apoptotic signalling pathway. Treatment of RPMI-8226 and MM.1R cells with SRT1720 induced phosphorylation of ATM (pATM) (Fig 3A) . We further confirmed these data by quantification of pATM using an enzyme-linked immunosorbent assay (ELISA): SRT1720 triggered a significant (3-to 4-fold) increase in pATM levels in MM.1R and RPMI-8226 cells (Fig 3B) . Examination of CHK2, a known downstream target of ATM, showed a marked increase in phosphorylation in response to SRT1720 (Fig 3C) , suggesting that SRT1720-induced MM cell apoptosis occurs via activation of the ATM-CHK2 signalling axis. Importantly, blockade of ATM using a biochemical inhibitor KU5593 abrogated SRT1720-induced decrease in cell viability (Fig 3D) . KU-55933 alone did not affect the viability of MM cells (data not shown). Taken together, these data suggest that the anti-MM activity of SRT1720 predominantly relies on the ATM-CHK2/caspase 8/9 signalling axis.
Besides activation of pro-apoptotic signalling cascades, we also examined whether SRT1720 affects growth and survival signalling pathways. Among many, the NF-κB-mediated signalling cascade has been shown to play a role in growth, survival, and drug resistance in MM cells (Chauhan et al, 1996; Hideshima et al, 2002) . Specifically, adhesion of MM cells to bone marrow stromal cells triggers NF-κB-mediated transcription and secretion of various MM cell growth factors (Chauhan et al, 1996) . In the present study, treatment of MM cells with SRT1720 significantly blocked NF-κB activity, evidenced by a decrease in IκB-α activity (Fig 3E; a 90% decrease in IκB-α activity was noted in SRT1720 vs. untreated cells). These findings suggest that the inhibition of NF-κB activity contributes to the overall anti-MM activity of SRT1720.
SRT1720 blocks migration of MM cells and angiogenesis
We and others have shown that migration and angiogenesis play an important role in the progression of MM (Podar et al, 2001; Vacca et al, 1999) . We investigated whether SRT1720 has anti-angiogenic activity. The effect of SRT1720 on these events was therefore examined using Transwell insert systems and in vitro tubule formation assays. Serum alone markedly increased MM.1S cell migration; importantly, SRT1720 significantly inhibited serum-dependent MM.1S cell migration, as evidenced by a decrease in the number of crystal violet-stained cells (Fig 4A) . Vascular endothelial growth factor (VEGF) is elevated in the MM bone marrow microenvironment, and triggers growth, migration, and angiogenesis in MM (Kumar et al, 2003; Podar et al, 2001; Podar et al, 2002; Rajkumar & Witzig 2000; Vacca et al, 1999) . We next examined whether SRT1720 affects VEGF-induced MM cell migration. VEGF alone markedly increased MM.1S cell migration; conversely, SRT1720 significantly (P = 0.04, n=3) inhibited VEGF-dependent MM cell migration (Fig 4B) . Cells remained >95% viable before and after performing the migration assay, excluding the possibility that drug-induced inhibition of migration was due to cell death.
We next utilized in vitro capillary-like tube structure formation assays to assess whether SRT1720 induces anti-angiogenic effects. Angiogenesis was measured in vitro using Matrigel capillary-like tube structure formation assays: HUVECs plated onto Matrigel differentiate and form capillary-like tube structures similar to in vivo neovascularization, a process dependent on cell-matrix interaction, cellular communication, and cellular motility. This assay provides evidence for anti-angiogenic effects of drugs. HUVECs were seeded in 96-well culture plates precoated with Matrigel; treated with vehicle (dimethyl sulphoxide, DMSO) or SRT1720 for 12 h; and then examined for tube formation using an inverted microscope. Tubule formation was markedly decreased in a dose-dependent manner in SRT1720-treated cells, but not in DMSO control cells (Fig 4C and 4D) . HUVEC cell viability was assessed using Trypan blue exclusion assay: < 5% cell death was observed after SRT1720 treatment, excluding the possibility that drug-induced inhibition of capillarytube formation was due to cell death. These findings suggest that SRT1720 blocks migration and angiogenesis.
SRT1720 inhibits human MM cell growth in vivo
Having shown that SRT1720 induced apoptosis in MM cells in vitro, we next examined the in vivo efficacy of SRT1720 treatment using a the human plasmacytoma MM.1S xenograft mouse model (Chauhan et al, 2008; LeBlanc et al, 2002) . A significant reduction (P=0.008) in tumour growth was observed in mice receiving SRT1720 treatment relative to untreated mice (Fig 5A) . Examination of the xenografted tumour sections showed that SRT1720, but not vehicle alone, increased the number of cleaved-caspase-3 positive cells (Fig 5B, left  panels) . Furthermore, a significant decrease in proliferation marker Ki-67-positive cells was also noted in tumour sections from SRT1720-treated mice relative to control mice (Fig 5B,  right panels) . In agreement with previously reported findings using SIRT1 activating agents (Funk et al, 2010; Yoshizaki et al, 2009) , we found no toxicity in the MM xenograft model even upon treatment of mice with SRT1720 at 200 mg/kg doses. These data demonstrate potent anti-tumour activity of SRT1720 in vivo.
Combination of SRT1720 with bortezomib, or dexamethasone triggers additive anti-MM activity
Human MM cell lines (MM.1S, RPMI-8226, and MM.1R) were treated with SRT1720 and bortezomib or dexamethasone for 24 h, followed by assessment for cell viability using MTT assays. For these studies, we utilized SRT1720, bortezomib, or dexamethasone at concentrations lower than their maximal cytotoxic concentration for each cell line. A more significant decrease in viability of all cell lines was observed in response to treatment with SRT1720 combined with low doses of bortezomib or dexamethasone (Fig 6A-6D ; n = 3) than with either agent alone. For example, treatment of MM.1S cells with low doses of SRT1720 (5 μM) and bortezomib (3 nM) triggered 60% decrease in viability, whereas only minimal cell killing was observed using either of these agents alone at these low concentrations (Fig 6A) . These data suggests that SRT1720 enhances the anti-MM activity of bortezomib or dexamethasone.
Discussion
Previous reports have demonstrated the anti-tumour activity of a SIRT1 activator (Bhardwaj et al, 2007; Harper et al, 2007; Sexton et al, 2006) . Mass-spectrometry based assays identified SRT1720 as a more potent, and selective small molecule activator of SIRT1 (Milne & Denu, 2008) . In the context of SRT1720-mediated biological effects, it is known that SRT1720 interacts directly with SIRT1 and triggers SIRT1-catalysed deacetylation via an allosteric mechanism (Dai et al, 2010) . Activation of SIRT1 by SIRT1 activating compounds is dependent on structural features of the substrate (Dai et al, 2010; Milne & Denu 2008; Pacholec et al, 2010) . Our data showed that SRT1720 markedly increases the SIRT1 deacetylating enzymatic activity in MM cells; conversely, pre-treatment of cells with nicotinamide (an inhibitor of SIRT1) blocked SRT1720-triggered activity. These findings are in agreement with prior biochemical and cell-based studies (Dai et al, 2010; Milne & Denu 2008) , suggesting that SIRT1 is a target of SRT1720.
Examination of SRT1720-induced biological sequelae in MM cells showed that SRT1720 decreases the viability of MM cell lines and primary patient tumour cells, without affecting normal PBMCs viability. Importantly, our data demonstrate anti-MM activity of SRT1720 in MM cell lines, including those sensitive and resistant to therapies, as well as representing distinct cytogenetic profiles. For example, we evaluated the isogenic cell lines, MM.1S (dexamethasone-sensitive) and MM.1R (dexamethasone-resistant), with t(14;16) translocation and MAF overexpression; RPMI-8266 with TP53, KRAS and EGFR mutations; INA-6, an interleukin-6-dependent cell line with NRAS activating mutation, and KMS12 t(11:14) with CCND1 deregulation (Avet-Loiseau et al, 2007; Bergsagel & Kuehl 2005; Burger et al, 2001; Davies et al, 2003; Greenstein et al, 2003; Hideshima et al, 2007) . The observed variation in IC 50 of SRT1720 for each cell line may be due to the heterogeneous nature of MM and drug resistance (Bergsagel et al, 1996; Bergsagel & Kuehl 2005; Davies et al, 2003; Hideshima et al, 2007) . In addition, the ATM abnormalities and/or p53 status in MM cells may contribute to SRT1720 anti-MM activity, and this issue remains to be defined. Nonetheless, our present findings showed similar responses in patient-derived tumour cells, including those resistant to therapies such as bortezomib, dexamethasone, or lenalidomide.
Mechanistic studies showed that anti-MM activity of SRT1720 is associated with activation of the caspase cascade, ROS generation, and apoptotic signalling involving the ATM/CHK2 pathway. Blockade of ATM abrogated SRT1720-induced MM cell death. Although ATM-CHK2 signalling plays a key role in mediating apoptosis triggered by SRT1720, the possibility that other signaling pathways are also activated by SRT1720 cannot be excluded. Overall, our current study suggests that the anti-MM activity of SRT1720 involves the ATM-CHK2/caspase 8/9 signalling axis.
In addition to inducing an apoptotic signalling cascade, SRT1720 also blocks one of the major growth and survival signalling cascades occurring via NF-κB. These findings demonstrate the ability of SRT1720 to simultaneously trigger apoptotic signalling, as well as block growth and survival pathways in MM cells. Our ongoing studies are focused on further delineating the mechanism of action of SRT1720 either alone or together with other agents.
Besides in vitro studies, we also examined anti-MM activity of SRT1720 in vivo. A marked growth inhibitory effect of SRT1720 was observed in a human plasmacytoma xenograft mouse model. In agreement with other in vivo animal model studies (Bhardwaj et al, 2007; Funk et al, 2010; Yoshizaki et al, 2009 ) using SIRT1-activating agents, no toxicity was observed during treatment of mice with SRT1720 at 200 mg/kg doses. The remarkable anti-MM activity of SRT1720 in vivo was confirmed by IHC analysis of tumours harvested from control and SRT1720-treated mice using molecular markers of apoptosis and proliferation (caspase-3 and Ki-67, respectively). The in vivo findings confirmed our in vitro data suggesting the potent anti-MM activity of SRT1720. Finally, we also examined the effect of SRT1720 in combination with a proteasome inhibitor, bortezomib, and a conventional anti-MM agent, dexamethasone. Our data showed that SRT1720 remarkably enhances the anti-MM activity of both bortezomib and dexamethasone.
Collectively, our preclinical studies demonstrate potent in vitro and in vivo anti-MM activity of SRT1720. These findings provide the framework for clinical trials of SRT1720, alone or in combination with bortezomib or dexamethasone, to increase response, overcome drug resistance, reduce side effects, and improve patient outcome in MM. (A) MM.1R and RPMI-8226 cells were treated with SRT1720 (7 μM) in the presence or absence of SIRT1 inhibitor nicotinamide for 6 h and harvested; extracts were then analysed for SIRT1 enzyme activity. (B) RPMI-8226 cells were treated with SRT1720 (7 μM) and harvested; protein lysates were subjected to immunoblot (IB) analysis with antibodies (Ab) specifically against acetylated p53 and GAPDH. Blots shown are representative of 3 independent experiments. (C) MM cell lines were treated with or without SIRT1720 at the indicated concentrations for 24h, followed by assessment for cell viability using MTT assays. Raw data from MTT assays were normalized to the percentage of viable cells in control (as 100%) versus drug-treated cells. Data presented are means ± standard deviation (SD) (n =3; P < 0.005 for all cell lines). (D) Purified patient MM cells (CD138-positive) were treated with SIRT1720 at the indicated concentrations for 24 h, and cell viability was measured. Raw data were normalized to the percentage of viable cells in control (as 100%) versus drug-treated cells. SRT1720 triggered specific reduction in the percentage of the viable primary MM cells versus untreated (control) cells. Values represent means of triplicate cultures ± SD (P < 0.05 for all patient samples). (E) PBMCs from healthy donors were treated with indicated concentrations of SIRT1720, and then analysed for viability using the MTT assay. Raw data from MTT assays were normalized to the percentage of viable cells in control (as 100%) versus drug-treated cells. Data presented are means ± SD (n =2; P < 0.05). (F) Normal B cells were treated with indicated concentrations of SIRT1720, and then analysed for viability using the MTT assay. Data presented are means ± SD (n =2; P < 0.05) (G) RPMI-8226 and MM.1R cell lines were treated with SRT1720 for 24 h, and then analysed for apoptosis using Annexin V/PI staining assay. (H and I) MM.1R and RPMI-8226 cells were treated with SRT1720 (7 μM) and harvested; whole cell lysates were subjected to immunoblot analysis with anti-PARP, or anti-GAPDH Abs. FL, full length; CF, cleaved fragment. Blots shown are representative of 3 independent experiments. (A) MM.1R and RPMI-8226 cells were treated with SRT1720 (7 μM) and harvested; total proteins were subjected to immunoblot analysis with anti-phosphorylated ATM (antipATM) or anti-ATM Abs. Blots shown are representative of three independent experiments. (B) MM.1R and RPMI-8226 cells were treated with SRT1720 (7 μM) and harvested; extracts were subjected to ELISA (P < 0.005; n = 3). (C) MM.1R and RPMI-8226 cells were treated with SRT1720 (7 μM) and harvested; total proteins were subjected to immunoblot analysis with anti-phosphorylated CHK2 (anti-pCHK2) or anti-CHK2 Abs. Blots shown are representative of three independent experiments. (D) MM.1R and RPMI-8226 cells were treated with SIRT1720 in the presence or absence of the ATM inhibitor KU55933 for 24 h, followed by assessment for cell viability using MTT assays. Data presented are means ± SD (n =3; P < 0.05). (E) MM.1R and RPMI-8226 cells were treated with SIRT1720 (7 μM) for 24 h, and extracts were then analysed for NF-κB activity by measuring phosphorylated IκB-α using both ELISA kits. Data presented are means ± SD (n =3; P < 0.05). (A) MM.1S cells were pretreated with 5 μM SRT1720 for 12h; cells (>90% viable) were then washed and cultured in serum-free medium. After a 2-h incubation, cells (viability > 90%) were plated on a fibronectin-coated polycarbonate membrane in the upper chamber of Transwell inserts, and exposed to serum-containing medium in the lower chamber for 4 h. Cells migrating to the bottom face of the membrane were fixed with 90% ethanol and stained with crystal violet (magnification: 10X/0.25 NA oil). A total of 3 randomly selected fields were examined for cells that had migrated from top to bottom chambers. The images arerepresentative of 3 experiments with similar results. (B) Cells were plated as in 'A' and the effect of SRT1720 on migration was assessed in the presence or absence of recombinant vascular endothelial growth factor (rVEGF). The bar graph represents quantification of migrated cells. Data presented are means ± SD (n = 3; P = 0.04 for control versus SRT1720-treated cells). Error bars represent SD. (C) HUVECs were cultured in the presence or absence of SRT1720 for 12 h, and then assessed for in vitro angiogenesis using Matrigel capillary-like tube structure formation assays (magnification: 4X/0.10 NA oil, media: EBM-2). is the images are representative of 3 experiments with similar results. In vitro angiogenesis is evidenced by capillary tube branch formation (dark brown). Data represents means ± SD (n=3; P < 0.05). (D) The bar graph represents quantification of capillary-like tube structure formation by vehicle alone and SRT1720-treated cells. Branch points in several random view fields/well were counted, values were averaged and statistically significant differences were measured using Student's t-test. Data presented are means ± SD 
